146 related articles for article (PubMed ID: 34002637)
21. Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team.
King LE; Farley E; Imazato M; Keefe J; Khan M; Ma M; Pihl KS; Sriraman P
AAPS J; 2014 May; 16(3):504-15. PubMed ID: 24687208
[TBL] [Abstract][Full Text] [Related]
22. Critical reagents: evolution of WRIB recommendations on critical reagents.
Amaravadi L
Bioanalysis; 2021 May; 13(10):741-743. PubMed ID: 33890504
[No Abstract] [Full Text] [Related]
23. Determination of ADC Concentration by Ligand-Binding Assays.
Chang HP; Shah DK
Methods Mol Biol; 2020; 2078():361-369. PubMed ID: 31643071
[TBL] [Abstract][Full Text] [Related]
24. Lot-to-lot reproducibility, stability and life cycle management of antibody reagents for flow cytometry.
Lanham DF
Bioanalysis; 2021 May; 13(10):745-759. PubMed ID: 34009005
[TBL] [Abstract][Full Text] [Related]
25. New insights on critical reagent optimization for antidrug antibody assays.
Rocha AG; Krynski K; Mancino A; Sciscione M; Beaver CJ
Bioanalysis; 2019 May; 11(9):815-823. PubMed ID: 30974951
[No Abstract] [Full Text] [Related]
26. Storage Conditions of Conjugated Reagents Can Impact Results of Immunogenicity Assays.
Kubiak RJ; Lee N; Zhu Y; Franch WR; Levitskaya SV; Krishnan SR; Abraham V; Akufongwe PF; Larkin CJ; White WI
J Immunol Res; 2016; 2016():1485615. PubMed ID: 27478855
[TBL] [Abstract][Full Text] [Related]
27. Bioanalytical Challenges in Support of Complex Modalities of Antibody-Based Therapeutics.
Zhu L; Glick J; Flarakos J
AAPS J; 2020 Oct; 22(6):130. PubMed ID: 33037499
[TBL] [Abstract][Full Text] [Related]
28. Fundamentals of large-molecule protein therapeutic bioanalysis using ligand-binding assays.
Thway TM
Bioanalysis; 2016; 8(1):11-7. PubMed ID: 26648176
[TBL] [Abstract][Full Text] [Related]
29. 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62).
Piccoli S; Mehta D; Vitaliti A; Allinson J; Amur S; Eck S; Green C; Hedrick M; Hopper S; Ji A; Joyce A; Litwin V; Maher K; Mathews J; Peng K; Safavi A; Wang YM; Zhang Y; Amaravadi L; Palackal N; Thankamony S; Beaver C; Bame E; Emrich T; Grimaldi C; Haulenbeek J; Joyce A; Kakkanaiah V; Lanham D; Maher K; Mayer A; Trampont PC; Vermet L; Dakappagari N; Fleener C; Garofolo F; Rogers C; Tangri S; Xu Y; Liang M; Rajadhyaksha M; Richards S; Schweighardt B; Purushothama S; Baltrukonis D; Brumm J; Cherry E; Delcarpini J; Gleason C; Kirshner S; Kubiak R; Pan L; Partridge M; Pedras-Vasconcelos J; Qu Q; Skibeli V; Saunders TS; Staack RF; Stubenrauch K; Torri A; Verthelyi D; Yan H; Gorovits B; Palmer R; Milton M; Long B; Corsaro B; Farrokhi V; Fiscella M; Henderson N; Jawa V; McNally J; Murphy R; Waldner H; Yang TY
Bioanalysis; 2019 Dec; 11(24):2207-2244. PubMed ID: 31820675
[TBL] [Abstract][Full Text] [Related]
30. Current industrial practices and regulatory requirements to assess analyte and reagent stability using ligand-binding assays.
Wang J; Nowatzke W; Ma M
Bioanalysis; 2015; 7(11):1371-84. PubMed ID: 26110710
[TBL] [Abstract][Full Text] [Related]
31. Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody.
Xiang Y; Parng C; Olson K; Seletskaia E; Gorovits B; Jani D; Caiazzo T; Joyce A; Donley J
AAPS J; 2019 Mar; 21(3):46. PubMed ID: 30927117
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal Antibody Reagent Stability and Expiry Recommendation Combining Experimental Data with Mathematical Modeling.
Fink M; Cannon EM; Hofmann C; Patel N; Pauley C; Troutman M; Rustandi RR; Shank-Retzlaff M; Loughney J; Verch T
AAPS J; 2020 Nov; 22(6):145. PubMed ID: 33161491
[TBL] [Abstract][Full Text] [Related]
33. Critical reagents in flow cytometry, instrumentation and application in drug discovery development.
Kakkanaiah VN; Matys K; Bennett P
Bioanalysis; 2021 May; 13(10):841-846. PubMed ID: 33890498
[TBL] [Abstract][Full Text] [Related]
34. Critical reagent inventory management system and web portal specifically optimized for supporting external clients.
Feauto JA; Davis A; Delhaye RC; Abdeen SJ; Gill HN; Colwell JE; Chiappetta M; Clor EE; Bowsher RR
Bioanalysis; 2022 Jun; 14(12):869-879. PubMed ID: 35904158
[TBL] [Abstract][Full Text] [Related]
35. Ligand-binding assays: risk of using a platform supported by a single vendor.
Yohrling J
Bioanalysis; 2009 Jun; 1(3):629-36. PubMed ID: 21083158
[TBL] [Abstract][Full Text] [Related]
36. A multifactorial screening strategy to identify anti-idiotypic reagents for bioanalytical support of antibody therapeutics.
Salimi-Moosavi H; Winters A; Abbott C; Patel J; Hager T; Patel V; Shih J; Zhuang Y; Ma M
Anal Biochem; 2015 Feb; 470():52-60. PubMed ID: 25447458
[TBL] [Abstract][Full Text] [Related]
37. Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody-reagent complexes at cut-point (CP-ARC) the missing piece?
Jordan G; Staack RF
Bioanalysis; 2020 Jul; 12(14):1021-1031. PubMed ID: 32633539
[TBL] [Abstract][Full Text] [Related]
38. EBF recommendation on practical management of critical reagents for PK ligand-binding assays.
Pihl S; van der Strate BW; Golob M; Vermet L; Jaitner B; Goodman J; Fjording MS; Timmerman P
Bioanalysis; 2018 Oct; 10(19):1557-1565. PubMed ID: 30226086
[TBL] [Abstract][Full Text] [Related]
39. Bioanalytical method validation considerations for LC-MS/MS assays of therapeutic proteins.
Duggan JX; Vazvaei F; Jenkins R
Bioanalysis; 2015; 7(11):1389-95. PubMed ID: 26110712
[TBL] [Abstract][Full Text] [Related]
40. Photolytic Labeling and Its Applications in Protein Drug Discovery and Development.
Chen Y; Topp EM
J Pharm Sci; 2019 Feb; 108(2):791-797. PubMed ID: 30339867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
